Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 1, 2016, Pages 88-101

  Fisher, S A ^a,b   Doree, C ^a,b   Taggart, D P ^c   Mathur, A ^d   Martin Rendon, E ^a,b,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD34 ANTIGEN; FIBRINOLYTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE HEART INFARCTION; ARTICLE; CELL THERAPY; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOM ERROR; SEQUENTIAL ANALYSIS; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; HEART LEFT VENTRICLE FUNCTION; META ANALYSIS (TOPIC); METHODOLOGY; MYOCARDIAL INFARCTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; HEART FAILURE; HOSPITALIZATION; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84966470364     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.344     Document Type: Article

References (45)

1. Hartwell, D. et al. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. Health Technol. Assess. 9(17), 1-99, iii-iv (2005).
2. Steinhauser, M.L. & Lee, R.T. Regeneration of the heart. EMBO Mol. Med. 3(12), 701-712 (2011).
3. Behfar, A., Crespo-Diaz, R., Terzic, A. & Gersh, B.J. Cell therapy for cardiac repair-lessons from clinical trials. Nat. Rev. Cardiol. 11(4), 232-246 (2014).
4. Jeevanantham, V. et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 126(5), 551-568 (2012).
5. Clifford, D.M. et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev. 2, CD006536 (2012).
6. Fisher, S.A. et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst. Rev. 4, CD007888 (2014).
7. Wen, Y., Meng, L., Xie, J. & Ouyang, J. Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis. Expert Opin. Biol. Ther. 11(5), 559-567 (2011).
8. de Jong, R. et al. Intracoronary infusion of encapsulated glucagon-like peptide-1-eluting mesenchymal stem cells preserves left ventricular function in a porcine model of acute myocardial infarction. Circ. Cardiovasc. Intervent. 7(5), 673-683 (2014).
9. Fisher, S.A., Zhang, H., Doree, C., Mathur, A. & Martin-Rendon, E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev. 9, CD006536 (2015).
10. Higgins, J.P.T. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT GSe, editor. Cochrane Collaboration. 2011, (2011).
11. Sterne, J.A. & Davey Smith, G. Sifting the evidence-what's wrong with significance tests? BMJ 322(7280), 226-231 (2001).
12. Pogue, J. & Yusuf, S. Overcoming the limitations of current metaanalysis of randomised controlled trials. Lancet 351(9095), 47-52 (1998).
13. Borm, G.F. & Donders, A.R. Updating meta-analyses leads to larger type I errors than publication bias. J. Clin. Epidemiol. 62(8), 825-830 e10 (2009).
14. Gyongyosi, M. et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ. Res. 116(8), 1346-1360 (2015).
15. DeJong, H., Bunton, P. & Hare, D.J. A systematic review of interventions used to treat catatonic symptoms in people with autistic spectrum disorders. J. Autism Dev. Disord. 44(9), 2127-2136 (2014).
16. Fisher, S.A., Doree, C., Mathur, A. & Martin-Rendon, E. Meta-analysis of cell therapy trials for patients with heart failure. Circ. Res. 116(8), 1361-1377 (2015).
17. Afzal, M.R. et al. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ. Res. 117, 558-575 (2015).
18. Delewi, R. et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur. Heart J. 35(15), 989-998 (2014).
19. Pedersen, F. et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J. Am. Coll. Cardiol. 64(20), 2101-2108 (2014).
20. Corrao, G., Ghirardi, A., Ibrahim, B., Merlino, L. & Maggioni, A.P. Short- and long-term mortality and hospital readmissions among patients with new hospitalization for heart failure: A population-based investigation from Italy. Int. J. Cardiol. 181, 81-87 (2015).
21. Abdel-Latif, A. et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch. Intern. Med. 167(10), 989-997 (2007).
22. Martin-Rendon, E. et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur. Heart J. 29(15), 1807-1818 (2008).
23. Review Manager (RevMan) [computer program]. 5.1 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration (2011).
24. Kandala, J. et al. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am. J. Cardiol. 112(2), 217-225 (2013).
25. Martin-Rendon, E. et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev. (4), CD006536 (2008).
26. Thorlund, K. et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int. J. Epidemiol. 38(1), 276-286 (2009).
27. Wetterslev, J., Thorlund, K., Brok, J. & Gluud, C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J. Clin. Epidemiol. 61(1), 64-75 (2008).
28. Pogue, J.M. & Yusuf, S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative metaanalysis. Control. Clin. Trials 18(6), 580-593 discussion 661-666 (1997).
29. Yusuf, S. Two decades of progress in preventing vascular disease. Lancet 360(9326), 2-3 (2002).
30. Keith, M.C. & Bolli, R. "String theory" of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ. Res. 116(7), 1216-1230 (2015).
31. Nowbar, A.N. et al. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ 348, g2688 (2014).
32. Moher, D., Schulz, K.F. & Altman, D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357(9263), 1191-1194 (2001).
33. Jennison, C. & Turnbull, B.W. Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat. Med. 22(6), 971-993 (2003).
34. Jennison, C. & Turnbull, B.W. Meta-analyses and adaptive group sequential designs in the clinical development process. J. Biopharm. Stat. 15(4), 537-558 (2005).
35. Brok, J., Thorlund, K., Gluud, C. & Wetterslev, J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J. Clin. Epidemiol. 61(8), 763-769 (2008).
36. Brok, J., Thorlund, K., Wetterslev, J. & Gluud, C. Apparently conclusive meta-analyses may be inconclusive-trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int. J. Epidemiol. 38(1), 287-298 (2009).
37. Engblom, H. et al. Rapid initial reduction of hyperenhanced myocardium after reperfused first myocardial infarction suggests recovery of the peri-infarction zone: one-year follow-up by MRI. Circ. Cardiovasc. Imaging 2(1), 47-55 (2009).
38. Haxhibeqiri-Karabdic, I., Hasanovic, A., Kabil, E. & Straus, S. Improvement of ejection fraction after coronary artery bypass grafting surgery in patients with impaired left ventricular function. Med. Arch. 68(5), 332-334 (2014).
39. Clarke, C.L. et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ. Cardiovasc. Qual. Outcomes 6(6), 680-686 (2013).
40. Hare, J.M. et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308(22), 2369-2379 (2012).
41. Bartunek, J. et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61(23), 2329-2338 (2013).
42. Makkar, R.R. et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379(9819), 895-904 (2012).
43. Higgins, J.P., Thompson, S.G., Deeks, J.J. & Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557-560 (2003).
44. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a metaanalysis. Stat. Med. 21(11), 1539-1558 (2002).
45. Kelly, P.J., Sooriyarachchi, M.R., Stallard, N. & Todd, S. A practical comparison of group-sequential and adaptive designs. J. Biopharm. Stat. 15(4), 719-738 (2005).